← Leaderboards
Nicole Mayer Hamblett
Seattle Children'S Hospital
$3,471,210
Attributed
$3,689,988
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $892.6K · FY2013–17$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$3,689,988 · 2
By mechanism
U01$3,252,432 · 1
R21$437,556 · 1
Top collaborators
- Alan R Hauser2 shared
Most similar at Seattle Children'S Hospital
Same institution · by research overlap
- Pradeep Singh$15,010,155
- Stephanie Duggins Davis$6,278,112
- Jennifer Rabbitts$6,740,496
- Christopher Hooper Goss$12,695,799
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventUnited States National Institutes Of HealthFundingMorbidity - Disease RatePseudomonas AeruginosaSpecimenControlled Clinical TrialsCystic FibrosisInfectionLungChronicAntimicrobialRandomizedRespiratoryAcuteChildren With Cystic FibrosisAntibioticsChildAntibiotic TherapyGenesLeadLifeCessation Of LifeAirway Obstruction
Grant awards (7)
OPTIMIZE - DCC$716,980
U01 · FY2017 · HL · contact PI
OPTIMIZE - DCC$662,936
U01 · FY2016 · HL · contact PI
Pseudomonas Genomic Signatures Associated With Persistence in Cystic Fibrosis$229,642
R21 · FY2016 · HL
OPTIMIZE - DCC$585,079
U01 · FY2015 · HL · contact PI
Pseudomonas Genomic Signatures Associated With Persistence in Cystic Fibrosis$207,914
R21 · FY2015 · HL
OPTIMIZE - DCC$582,111
U01 · FY2014 · HL · contact PI
OPTIMIZE - DCC$705,326
U01 · FY2013 · HL · contact PI